STOCK TITAN

PRF Technologies Ltd. (PRFX) Stock Price, News & Analysis

PRFX NASDAQ
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
82 252 sessions, November 20, 2025 to November 20, 2026
Largest daily move
+119% close of May 29, 2026
1-year change
-89% closing prices, November 20, 2025 to November 20, 2026
1-month change
-34.3% closing prices, October 20, 2026 to November 20, 2026

Company Description

PainReform Ltd. (Nasdaq: PRFX) is a specialty pharmaceutical and technology company whose activities span post-surgical pain management and AI-driven energy analytics. According to its public disclosures, the company focuses on the reformulation of established therapeutics using proprietary extended-release drug-delivery systems, and on the development of AI-based software that helps monitor, forecast, and optimize energy use in solar-integrated environments through its DeepSolar platform.

In its pharmaceutical division, PainReform develops programs that leverage a proprietary extended-release drug-delivery system intended to provide prolonged post-surgical pain relief while minimizing the need for repeated dosing and reducing reliance on opioids. The company has described itself as a clinical-stage specialty pharmaceutical company and has highlighted its focus on non-opiate approaches to pain management in surgical settings.

One of PainReform’s key pharmaceutical assets is PRF-110, described as an oil-based, viscous, clear solution based on the local anesthetic ropivacaine and targeting the post-operative pain relief market. PRF-110 is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia. The company has reported that PRF-110 demonstrated meaningful efficacy in the early part of the postoperative period in a bunionectomy trial and that it is conducting additional research and development to refine the program.

PainReform has also expanded into ophthalmology through a majority investment in LayerBio, Inc., a biotechnology company advancing sustained-release drug delivery technologies in ophthalmology. LayerBio’s lead product candidate, OcuRing™-K, is a patent-protected, sustained-release intraocular ring designed to deliver ketorolac, a non-opiate, non-steroidal anti-inflammatory and analgesic drug, following cataract surgery. OcuRing-K is placed intraoperatively during cataract procedures and is described as a “dropless” therapy intended to replace traditional post-surgical eye-drop regimens that often involve multiple daily corticosteroid and NSAID drops.

The OcuRing-K platform is designed to provide controlled, localized, and extended release of therapy directly at the surgical site, with the goal of eliminating patient-administered drops, improving compliance, and reducing systemic exposure. PainReform has reported that LayerBio’s technology allows extended drug release from a single application, offers site-specific delivery to maximize local effect, and uses a biodegradable design that eliminates the need for device removal. Company communications also state that the platform can support delivery of a range of ocular therapeutics, including NSAIDs, antibiotics, steroids, and anti-VEGF agents.

PainReform and LayerBio have disclosed a development path for OcuRing-K that includes preclinical studies and clinical trials. Preclinical rabbit studies and a Phase I clinical study in cataract surgery patients have been reported to show a favorable safety profile for OcuRing™-K’s drop-less, sustained-release ocular drug-delivery platform, with no treatment-emergent adverse events related to the study drug and no serious adverse events identified in the Phase I study. The investigational product and intraocular lens devices were reported to remain properly positioned in all treated eyes. Based on these findings, the company has indicated that it is advancing toward later-stage development and IND-enabling activities.

Beyond OcuRing-K, PainReform has described LayerBio’s sustained-release, polymer matrix platform as capable of incorporating a variety of drug entities, including corticosteroids and NSAIDs, reinforcing the potential for multi-drug loading and broader ophthalmic applications. Company statements reference the long-term goal of reducing or eliminating reliance on medicated eye drops in cataract surgery and potentially in other ophthalmic indications.

On the energy side of its business, PainReform operates the DeepSolar platform, which it characterizes as a developer of advanced digital-asset-management technologies for utility-scale solar plants. DeepSolar’s AI-driven algorithms are described as transforming complex operational data into insights that detect issues, forecast production, and support decision-making to maximize asset performance and profitability. The company reports that DeepSolar delivers advanced software solutions that enable both consumers and enterprises to monitor, forecast, and optimize energy consumption, particularly in solar-integrated environments.

DeepSolar’s activities include the development of DeepSolar Predict, an AI-based forecasting module built specifically for photovoltaic systems and advanced within the NVIDIA Connect program. According to company press releases, DeepSolar Predict is designed to enhance weather-driven energy production forecasts and help solar-asset managers reduce imbalance risks and improve profitability by combining advanced weather modeling with AI-optimized computation. PainReform has also described DeepSolar’s participation in the NVIDIA Connect program, which provides access to AI frameworks, development tools, and engineering support.

In addition, DeepSolar has introduced Smart TDD, an advanced solar technical due diligence service that aims to provide faster and more comprehensive assessments of solar asset performance and risk. Company materials state that Smart TDD is engineered to audit complete data coverage across components and operational history, apply AI-driven analytics with physics-based modeling and expert review, and deliver prioritized findings with rapid turnaround. DeepSolar has also advanced an automated reporting engine intended to consolidate and interpret data from multiple sources and generate tailored performance reports for stakeholders in minutes.

PainReform has reported that DeepSolar’s software platform has demonstrated the ability to enhance energy production and reduce operations and maintenance costs, and that it has progressed from pilot projects into initial commercial agreements, such as a 92MW pilot project with Econergy Renewable Energy in Romania that advanced into a commercial customer agreement. The company positions this dual focus on specialty pharmaceuticals and renewable-energy analytics as a strategic commitment to applying precision technology across healthcare and sustainable energy sectors.

Business Segments

Based on its public communications, PainReform’s activities can be viewed in two main areas:

  • Specialty pharmaceutical programs focused on reformulating established therapeutics and developing sustained-release drug-delivery technologies for post-surgical pain and ophthalmic indications, including PRF-110 and the OcuRing-K platform via its majority-owned subsidiary LayerBio.
  • AI-driven energy analytics through the DeepSolar platform, which develops digital-asset-management technologies, forecasting tools such as DeepSolar Predict, and services such as Smart TDD and automated reporting for solar assets and energy optimization.

Regulatory and Listing Context

PainReform Ltd. files reports with the U.S. Securities and Exchange Commission as a foreign private issuer, including multiple Form 6-K current reports that furnish press releases, financial statements, and transaction disclosures. The company’s ordinary shares trade on Nasdaq under the symbol PRFX. Its SEC filings reference registration statements on Form F-3 and Form S-8, reflecting its status as a listed issuer accessing U.S. capital markets.

Stock Performance

$0.4910
+3.19%
+0.0152
After hoursChange vs the $0.4758 closeLast updated: at
-89%
Performance 1 year
3.5M
Shares outstanding As of September 2, 2026.

PRF Technologies Ltd. (PRFX) closed at $0.4758 on November 20, 2026. Over the past 12 months, the price has lost 89.0%.

See what a $1,000 investment in PRFX would be worth today

Average down calculator for PRFX

PRFX Metrics & Rankings

Price returns through November 20, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Latest News

PRF Technologies Ltd. has 10 recent news articles. Of the recent coverage, 7 articles coincided with positive price movement and 3 with negative movement. Key topics include partnership, AI, clinical trial. View all PRFX news →

SEC Filings

PRF Technologies Ltd. has filed 10 recent SEC filings, including 7 Form 6-K, 2 Form SCHEDULE 13D/A, 1 Form SCHEDULE 13D. The most recent filing was submitted on . SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all PRFX SEC filings →

Financial Highlights

PRF Technologies Ltd. generated $17K in revenue in FY2025, operating income reached -$5.1M, and net income was -$5.0M. Diluted earnings per share stood at -$7.47. The company generated -$4.0M in operating cash flow. The current ratio was 1.78, measuring current assets divided by current liabilities.

$17K
Revenue (FY2025)
-$5.0M
Net Income (FY2025)
-$4.0M
Operating Cash Flow
-$53K
Gross Profit (FY2025)

Upcoming Events

MAY
08
May 8, 2027 Corporate

Nasdaq delisting deadline

Final date the Nasdaq Panel may grant an exception to PRF Technologies' sub-$1 compliance deficiency; hearing outcome pending.

PRF Technologies Ltd. has 1 upcoming scheduled event. The next event, "Nasdaq delisting deadline", is scheduled for May 8, 2027 (in 168 days). Investors can track these dates to stay informed about potential catalysts that may affect the PRFX stock price.

Short Interest History

Last 12 Months

Short interest in PRF Technologies Ltd. (PRFX) currently stands at 12.8 thousand shares, down 35.9% from the previous reporting period, representing 0.4% of the float. Since the latest stock split, short interest has decreased by 83.7%, measured from February 2026.

Days to Cover History

Last 12 Months

Days to cover for PRF Technologies Ltd. (PRFX) currently stands at 1.0 days. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has decreased by 60.6%. Across the settlements charted above, it has ranged from 1.0 to 3.3 days.

PRFX Company Profile & Sector Positioning

PRF Technologies Ltd. (PRFX) operates in the Drug Manufacturers - Specialty & Generic industry within the broader Healthcare sector and is listed on the NASDAQ.

Investors comparing PRFX often look at related companies in the same sector, including Apimeds Pharmaceuticals US, Inc. (APUS), Redhill Biopharma Ltd. (RDHL), Gelteq Limited (GELS), Akanda Corp. (AKAN), and China SXT Pharmaceuticals, Inc. (SXTC). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate PRFX's relative position within its industry.

Frequently Asked Questions

The current stock price of PRF Technologies Ltd. (PRFX) is $0.4910 in after-hours trading as of November 20, 2026.

The market cap of PRF Technologies Ltd. (PRFX) is approximately $1.7M. Learn more about what market capitalization means .

The FY2025 revenue of PRF Technologies Ltd. (PRFX) is $17K, from its most recent completed fiscal year.

The FY2025 net income of PRF Technologies Ltd. (PRFX) is -$5.0M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of PRF Technologies Ltd. (PRFX) is -$7.47 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of PRF Technologies Ltd. (PRFX) is -$4.0M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The current ratio of PRF Technologies Ltd. (PRFX), current assets divided by current liabilities, was 1.78 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The gross profit of PRF Technologies Ltd. (PRFX) is -$53K for FY2025, its most recent completed fiscal year.

The operating income of PRF Technologies Ltd. (PRFX) is -$5.1M for FY2025, its most recent completed fiscal year. Learn about operating income.

According to its public disclosures, PainReform Ltd. focuses on the reformulation of established therapeutics using proprietary extended-release drug-delivery systems for post-surgical pain management, and on the development of AI-driven energy optimization technologies through its DeepSolar platform.

PRF-110 is described by the company as an oil-based, viscous, clear solution based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. It is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.

OcuRing-K is LayerBio’s lead product candidate, described as a patent-protected, sustained-release intraocular ring delivering ketorolac for pain and inflammation control following cataract surgery. It is intended as a dropless, single-application alternative to traditional multi-week corticosteroid and NSAID eye-drop regimens.

PainReform and LayerBio have reported that preclinical rabbit studies and a Phase I clinical study in cataract surgery patients showed a favorable safety profile for the OcuRing-K drop-less, sustained-release ocular drug-delivery platform, with no treatment-emergent adverse events related to the study drug and no serious adverse events observed in the Phase I study.

Company materials state that its pharmaceutical programs leverage a proprietary extended-release drug-delivery system intended to provide prolonged post-surgical pain relief while minimizing the need for repeated dosing and reducing reliance on opioids. In the ophthalmic setting, LayerBio’s platform is designed for site-specific, sustained release from a single intraoperative application.

DeepSolar is PainReform’s solar energy business unit and platform that develops advanced digital-asset-management technologies for utility-scale solar plants. It uses AI-driven algorithms to transform complex operational data into insights that detect issues, forecast production, and support decisions to optimize asset performance and energy consumption.

DeepSolar Predict is described as an AI-based forecasting module built specifically for photovoltaic systems. Developed within the NVIDIA Connect program, it is designed to enhance weather-driven energy production forecasts and help solar-asset managers reduce imbalance risks and improve profitability.

Smart TDD is DeepSolar’s advanced solar Technical Due Diligence service. Company disclosures state that it aims to provide faster, more accurate, and more comprehensive assessments of solar asset performance and risk by combining complete data coverage, AI-driven analytics, physics-based modeling, and expert engineering review.

PainReform Ltd.’s ordinary shares trade on Nasdaq under the ticker symbol PRFX, as indicated in its press releases and SEC filings.